Cryoneurolysis for Facet Mediated Chronic Low Back Pain

Low Back Pain Clinical Trial

Official title:

A Single-center, Randomized, Pilot Study to Assess Iovera° Lumbar Medial Branch Cryoneurolysis vs Lumbar Radiofrequency Ablation for Facet Mediated Chronic Low Back Pain

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06016127
• Other study ID #: CRS-107
• Status: Completed
• Phase: N/A
• Start date: June 18, 2022
• Est. completion date: October 23, 2023

Study information

• Verified date: January 2024
• Source: Medical Pain Management Services, PLLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single-center, randomized, pilot study in adult subjects with facet mediated CLBP. Thirty (30) subjects are planned for initial enrollment and will be randomized 1:1 to receive ioveraº medial branch cryoneurolysis or radiofrequency ablation.

Description:

This is a single-center, randomized, pilot study in adult subjects with facet mediated CLBP. Thirty (30) subjects are planned for initial enrollment and will be randomized 1:1 to receive ioveraº medial branch cryoneurolysis or radiofrequency ablation. This study is designed to determine if a full efficacy RCT can be successfully conducted using the procedures and protocols described in the current pilot study protocol, or if protocol modifications are necessary before moving forward with a full efficacy RCT. Furthermore, the study will assess the feasibility of the outcome measurements employed, construct a foundation for sample size calculation, and the acceptability/practicality of conducting the full efficacy RCT. Randomization to treatment groups according to the randomization assignment will be performed on the day of treatment. The treatment groups are: - Group 1: subjects will receive iovera° cryoneurolysis to the medial branch nerves of the lumbar spine - Group 2: subjects will receive RFA to the medial branch nerves of the lumbar spine

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: October 23, 2023
• Est. primary completion date: October 23, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male or female volunteers, at least 18 years of age at screening

2. Primary complaint of axial low-back pain suggestive of unilateral or bilateral facet joint involvement (i.e., facet mediated CLBP)

3. Low back pain is chronic (i.e., > 3 months' duration)

4. Low back pain score of = 4 (i.e., moderate pain) on the 0 to 10 NRS or functional impairment at screening

5. Successful trial of two diagnostic medial branch blocks consisting of two positive blocks with local anesthetic only (i.e., no steroids) that results in at least 50% relief of primary (index) pain for the duration of the local anesthetic used or history of a positive response to prior radiofrequency treatment (i.e., = 6 months prior to enrollment)

6. Failure of at least three months of conservative non-operative therapy (e.g., physical therapy, chiropractic care, spinal injections, NSAIDs or other appropriate analgesics),

7. Able to provide informed consent, adhere to the study visit schedule, and complete all study assessments

Exclusion Criteria:

1. Active workers' compensation, personal injury, Social Security disability insurance (SSDI), or other litigation/compensation related to the spine

2. Serious spinal disorders (verified on magnetic resonance imaging (MRI)) that may

impact outcomes, including any of the following:

1. Suspected cauda equina syndrome (e.g., bowel/bladder dysfunction)

2. Infection

3. Tumor

4. Traumatic fracture

5. Systemic inflammatory spondyloarthropathy

6. Lumbar radiculopathy/radiculitis (i.e., root irritation and deficit)

7. Neurogenic claudication

3. Prior lumbar spinal fusion surgery

4. Comorbidity that, in the judgment of the Investigator, may affect the subject's ability to participate in the study including lumbar radiculopathy and neuropathic pain disorder

5. Currently pregnant, nursing, or planning to become pregnant during the study

6. Known contraindication to study devices, including any of the following:

1. Cryoglobulinemia

2. Paroxysmal cold hemoglobinuria

3. Cold urticaria

4. Raynaud's disease

5. Open and/or infected wounds at or near the treatment site

6. Coagulopathy

7. 3.5-inch needle cannot be used in the low back region because of habitus

8. Severe chronic pain disorder that in the opinion of the investigator may impact postsurgical outcomes

9. Presence of any of the following:

1. Spinal neurostimulator

2. Intrathecal analgesic drug pump

10. Current manifestation of poorly controlled mental illness that in the opinion of the investigator may meaningfully impact treatment outcomes, including any of the

following:

1. Mood disorder (e.g., major depression, bipolar)

2. Psychotic disorder (e.g., schizophrenia)

11. Subject received other spine intervention/therapies in the 30 days prior to block administration (e.g., spinal injections, minimally invasive therapies, surgical therapies)

12. Subject received radiofrequency ablation in the low back region = 6 months before study enrollment

13. History, suspicion, or clinical manifestation of:

1. Alcohol abuse or dependence

2. Illicit drug use

3. Opioid abuse or dependence (=40 mg MED PO/day in past 30 days) Given the COVID-19 pandemic, the subject must be medically fit/cleared for treatment by the investigator. If there is a concern about a subject's recent or potential exposure to COVID-19, or if the subject is not medically fit/cleared for treatment due to suspected COVID-19 illness/symptoms (or other serious illness), the subject must be excluded per Exclusion criterion #4.

Related Conditions & MeSH terms

• Arthralgia
• Back Pain
• Facet Joint Pain
• Low Back Pain

Intervention

Device:
• iovera system
The iovera° system consists of a reusable, portable Handpiece, along with single patient use sterile Smart Tips (i.e., cryoprobes) and disposable nitrous oxide (N2O) cartridges. The iovera° system produces the desired effect through initiation of a cooling cycle. Each cooling cycle is initiated by fully inserting the Smart Tip into the selected procedure site and activating the cryogen flow. The Smart Tip needles are made of stainless steel and have a closed tip, fully enclosing the cryogen. The "190" Smart Tip will be used in this study.
• Radiofrequency ablation
The RFA system consists of a Cosman, G4 Generator. The needles used are 20-gauge, 10cm long with a 10mm active tip manufactured by Cosman. A grounding pad, also manufactured by Cosman, is placed on the upper thigh for each procedure and connected to the G4 Generator.

Locations

Country	Name	City	State
United States	The Albany & Saratoga Centers For Pain Management	Saratoga Springs	New York

Sponsors (2)

Lead Sponsor	Collaborator
Medical Pain Management Services, PLLC	Pacira Pharmaceuticals, Inc

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Change in functional disability	Function disability will be measured by the Oswestry Disability Index. The score ranges from 0-50, with lower scores reflecting milder disability.	0-12 months
Other	Change in Patients' Global Impression of Change	The Patients' Global Impression of Change (PGIC) is a 7-point patient self-reporting scale of overall change in activity limitations, symptoms, emotions, and quality of life ranging from 1) no change 2) hardly any change 3) no noticeable change 4) change has not made any real difference 5) a slight but noticeable change 6) a definite improvement 7) considerable improvement.; The scale also assesses degree of change since beginning care (0=much better, 10=much worse).	0-12 months
Other	Satisfaction with pain management	Subject satisfaction with pain management as measured on a scale ranging from 1) extremely dissatisfied 2) dissatisfied 3) neither satisfied nor dissatisfied 4) satisfied 5) extremely satisfied.	0-12 months
Primary	Safety of cryoneurolysis as compared to radiofrequency ablation (RFA)	Safety will be assessed as the number of subjects with reported treatment-related adverse related to cryoneurolysis or RFA.	0-12 months
Secondary	Change in pain intensity as measured by 11-point Numeric Rating Scale (NRs)	Subjects will evaluate their pain in the low back region using an 11-point Numeric Rating Scale (NRS), where 0=no pain and 10=worst possible pain.; Subjects will evaluate how much pain they are currently experiencing and their worst and average level of pain over the past 24 hours.	0-12 months